PTU - Polskie Towarzystwo Urologiczne
list of articles:

Article published in Urologia Polska 1997/50/4.


Jarosław Ćwikła, Marek Żabiński 1, Sławomir D±browski 2, Leszek Królicki 3
Zakład Roentgenodiagnostyki i Medycyny Nuklearnej
CMKP Warszawa, PSK nr 2 im. prof. Adama Grucy
Kierownik: lek. med. J. Szawdyn
1 Oddział Urologii
Zakład Opieki Zdrowotnej - Szpital Miejski im. Mikołaja Kopernika
10-045 Olsztyn, al. Niepodległo¶ci 44
Kierownik: lek. med. M. Żabiński
2 Katedra Mikrobiologii, Politechnika Gdańska
80-952 Gdańsk, ul. Narutowicza 11/12
Kierownik: prof. dr hab. J. Kur
3 Zakład Medycyny Nuklearnej i Rezonansu Magnetycznego
Wojewódzki Zespół Publicznych Zakładów Opieki Zdrowotnej
03-242 Warszawa, Kondratowicza 8
Kierownik: prof. dr hab. L. Królicki


kidney RCC multidrug resistance mRNA MDR-1, RT-PCR


Objective. The failure of chemotherapy to cure more than a minority of
tumours is predominantly due to drug resistance. Cancers with overexpression
of P-glycoprotein (Pgp) are resistant to a structurally and functionally diverse
group of chemotherapeutic compounds which include anthracyclines, vinca
alcaloids and actinomycin D. Pgp is encoded by MDR-1 gene. Normally high
levels of mRNA MDR-1 gene expression was found in the normal human kidney,
in the proximal tube epithelium. This tissue is usually an origin of most renal
cell cancers. The renal cell carcinoma is a well-known tumour type demonstrating
usually Pgp overexpression and usually it is resistant to standard chemotherapy.
Some previous reports find out that overexpression of Pgp in renal tumours
may be variable, most likely depending of tumour type and differentiation.
Tumours reported to express no Pgp could be considered to appropriate
chemotherapy. The aim of this initial study is estimation of mRNA MDR-1
gene expression in renal cell carcinoma (RCC) patients.
Patients and Methods. We considered in this study 10 patients with
histopathological confirmation of RCC. All patients were treated by standard
radical nephrectomy. Specimens of the tumour tissue were harvested during
operation immediately after removed affected kidney. Each tumour samples
were assessed to presence mRNA MDR-1 gene expression by specific semi-
quantitative method, based on the reverse transcryptase ? polymerase chain
reaction (RT-PCR).
Results. The detectable level of MDR-1 expression was found in 5 patients.
Others had no detectable levels.
Conclusion. In this initial study we would like to presented a potential
role of assessement mRNA MDR-1 gene expression measurement in untreated
RCC patients. This simple and sensitive method seems to by promising tool
in detecting MDR-1 gene expression and has a value in potential further
chemotherapy in patients with RCC.


  1. [1] Dano, K.: Bloch. Actwe Outward Transport of Daunomycin in Resistant Ehrlich
  2. Ascites tumour cells. Biophys. Acta, 1973,323 466-483.
  3. [2] de Kernion, J. B.:Renal Tumors. W WalshP. C. (ed): Campbell's Urology. 5-thed.,
  4. vol. 2. Philadelphia, Pa. Sounders 1986,1294-1342.
  5. [3] DeVita, V. T.: W Cancer: Principles and Practice of Oncology, eds V. T. DeVita,
  6. S. Hellman and S. A. Rosenberg, Lippincrott, Philadelphia 1989, 276-300.
  7. [4] Fojo,A. T, Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M.M., Pastan, I.:
  8. Expression of multidrug-resistance gene in human tumours and tissue. Proc. Natl.
  9. Acad. Sci. USA, 1987, 84, 265-269.
  10. [5] Goldstein, L. ]., Galski, A., Fojo, M.: Expression ofmultidrug resistance gen in
  11. human cancers. J. Natl. Cancer Inst., 1989, 81,116-124.
  12. [6] Hermanek, P, Sobin, L. H. (eds): International Union Against Cancer. TNM Clas-
  13. sification of malignant tumors. Ed 4, Springer-Verlag, Berlin, 1987.
  14. [7] Kakehi, Y, Kanamaru, H., Yoshida, O.: Measurement of multidrug-resistance
  15. mRNA in urogenital cancers; Elevated expression in renal cell carcionoma is associa-
  16. ted with intrinsic drug resistance. J. Urol., 1988,139,862-865.
  17. [8] Kawasaki, E. S.: Amplification of RNA se±uences via complementary DNA (cDNA).
  18. Amplification a formum for PCR Users., 1989,2,4-6.
  19. [9] Mickisch, G., Rohrrich, K., Kossig, J.: Mechanism and modulation ofmultidrug
  20. resistance in primary human renal carcinoma. J. Urol., 1990, 144, 755-759.
  21. [10] Mickisch, G. H., Gaast, A., van der Noordzij, M. A., Scheltema, J. M. W., Stoter,
  22. G., Schroder, F. H.: Dexverapamil to surmount vinblastine ? resistance in renal cell
  23. carcinoma. Cancer Res. Clin. Oncol., 1994,120, Suppl. R8.
  24. [11] Morello, D., Duprey, P, Israel, A., Babinet, C: Immunogenetics. 1985,22,441-452.
  25. [12] Naito, S., Sakamoto, N., Kotoh, S., Goto, K., Matsumoto, T., Kumazawa, J.: Expres-
  26. sion ofP-Glycoprotein and Multidrug Resistance in renal cell carcinoma. Eur. Urol.,
  27. 1993, 24, 156-160.
  28. [13] Noonan, K. E., Beck, C, Holzmayer, T. A., Chin, J. E., Wunder, J. S.: Quantitative
  29. analysis of MDR-1 (multidrug resistance) gene expression in human tumors bypoly-
  30. merase chain reaction. Proc. Nat. Acad. Sci., USA., 1990,87, 7160-7164.
  31. [14] Robson, C, Churchill, B. M., Anderson, W.: The results of radical nephrectomy for
  32. renal cell carcinoma. J. Urol, 1969,101, 297-301.
  33. [15] Rochlitz, C. E, Lobeck, H., Peter, S., Reuter, ].: Multiple drug resistance gene expres-
  34. sion in human renal cell cancer is associated with the histologic subtype. Cancer,
  35. 1992, 69, 2993-2998.
  36. [16] Roninson, I. B., Chin, J. E., Choi, K., Gros, R, Housman, D. E., Fojo, A., Shen, D.
  37. W., Gottesman, M. M., Pastan, I.: Isolation of human mdr DNA seauences amplified
  38. in multidrug-resistant KB carcinoma cells. Proc. Natl. Acad. Sci., USA, 1986,83,
  39. 4538-4542.
  40. [17] Sambrok, }., Fritsch, E. E, Maniatis, T.: Molecular Clonning 9. 14-9,19. Cold
  41. Spring Harbor Laboratory Press, 1989.
  42. [18] Stenzl, A., deKemion, J. B.: Pathology, biology and clinical staging of renal cell
  43. carcinoma. Semin. Oncol., 1989,16, 3-11.
  44. [19] Ueda, K., Cardarelli, C, Gottesman, M. M. and Pastan, L: Expression of full
  45. lenght cDNAfor the human MDR-1 gene confers resistance to colchicine, doxorubicin
  46. andvinblastine. Proc. Natl. Acad. Sci., USA., 1987, 84, 3004-3008.
  47. [20] Volm, M., Pommerenke, E. W., Efferth, T., Lorkę, H., Mattern, ].: Circum-vention
  48. of multi-drug resistance in human kidney and kidney carcinoma in nitro. Cancer,
  49. 1991, 67, 2484-2489.